p53 in the DNA-Damage-Repair Process

Ashley B. Williams^{1,2} and Björn Schumacher^{1,2}

¹Medical Faculty, Institute for Genome Stability in Ageing and Disease, University of Cologne, 50931 Cologne, Germany

²Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC) and Systems Biology of Ageing Cologne, University of Cologne, 50931 Cologne, Germany

Correspondence: bjoern.schumacher@uni-koeln.de

The cells in the human body are continuously challenged by a variety of genotoxic attacks. Erroneous repair of the DNA can lead to mutations and chromosomal aberrations that can alter the functions of tumor suppressor genes or oncogenes, thus causing cancer development. As a central tumor suppressor, p53 guards the genome by orchestrating a variety of DNA-damage-response (DDR) mechanisms. Already early in metazoan evolution, p53 started controlling the apoptotic demise of genomically compromised cells. p53 plays a prominent role as a facilitator of DNA repair by halting the cell cycle to allow time for the repair machineries to restore genome stability. In addition, p53 took on diverse roles to also directly impact the activity of various DNA-repair systems. It thus appears as if p53 is multitasking in providing protection from cancer development by maintaining genome stability.

The loss of p53 is a major driver of cancer development mainly because, in the absence of this “guardian of the genome,” cells are no longer adequately protected from mutations and genomic aberrations. Already the most ancestral forms of p53 have acquired functions in responding to DNA damage. Intriguingly, the evolutionary occurrence of p53 homologs appears to be associated with multicellularity. With the advent of metazoans, genome maintenance became a specialized task with distinct requirements in germ cells and somatic tissues. The function of p53 in the nematode *Caenorhabditis elegans* particularly well exemplifies the distinct requirements for genome maintenance in distinct tissues of metazoans and is,

therefore, discussed as an instructive instance of ancestral p53 function.

In the nematode, DNA-damage checkpoints respond to DNA damage specifically in the germ cells (Gartner et al. 2000). When ionizing radiation (IR) induces DNA double-strand breaks (DSBs), mitotically dividing germ cells arrest through conserved DNA-damage checkpoint activity. The cell-cycle arrest is confined to the germ stem cell compartment that is maintained in the distal zone of the germline. Once the damage is repaired, the germ stem cells resume proliferation. Only cells during the late stages of meiotic pachytene undergo apoptosis in the presence of DSBs. Although the IR-induced cell-cycle arrest is unaffected by

Editors: Guillermina Lozano and Arnold J. Levine

Additional Perspectives on The p53 Protein available at www.perspectivesinmedicine.org

Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a026070

Cite this article as *Cold Spring Harb Perspect Med* 2016;6:a026070

A.B. Williams and B. Schumacher

the presence or absence of the *C. elegans* p53 homolog CEP-1, it is required for DNA-damage-induced apoptosis (Derry et al. 2001; Schumacher et al. 2001). The proapoptotic action of CEP-1/p53 is strictly confined to meiotic pachytene cells. Before meiotic cells reach that stage, the translational repressor GLD-1 prevents *cep-1/p53* mRNA from being translated (Schumacher et al. 2005a). Only when GLD-1 is switched off in late pachytene does CEP-1/p53 protein become available. In case DSBs are present, CEP-1/p53 transcriptionally induces the BH3-only domain proteins EGL-1 and CED-13 (Hofmann et al. 2002; Schumacher et al. 2005b). Intriguingly, physiological DSBs are induced to ignite meiotic recombination by the endonuclease SPO-11. The orderly recombination events must be completed within the pachytene stage. Only failure in resolving recombination intermediates will lead to persistent DSBs in late pachytene cells. CEP-1/p53 is thus available to cull such cells that might otherwise result in genomically compromised oocytes. As oocytes are the cell type that major resources are deposited into by the mother, CEP-1/p53 safeguards the investments by eliminating genomically compromised cells before any major investments are made; thus, CEP-1/p53 fulfills an important function in ensuring the inheritance of stable genomes.

Although the ancestral p53 specifically surveys the presence of DSBs in meiotic cells, it responds to other types of DNA lesions also in mitotic cells. In contrast to IR, UV induces cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts (6-4PPs), both of which lead to distortions in the DNA double helix and pose obstacles for both replication and transcription. CEP-1/p53 not only mediates apoptosis but is also required for arresting the cell cycle on UV-induced lesions (Derry et al. 2007). Halting the cell cycle is a prerequisite for repairing DNA lesions. Although on DSB formation only the two proapoptotic BH3-only proteins are transcriptionally induced through CEP-1/p53, transcriptome experiments following UV irradiation defined a range of genes that are induced or repressed dependent on CEP-1/p53 (Derry

et al. 2007). The growth-arrest-specific 1 (Gas1) homolog *phg-1* was defined as a CEP-1/p53 target gene required for halting cell proliferation.

Also in mammals, p53 is stabilized and activated by DNA-damage checkpoint signaling following a range of genotoxic insults (reviewed in Shiloh et al. 2013). Although the proapoptotic function of p53 is highly conserved throughout evolution by transcriptional induction of BH3-only domain proteins that execute the programmed cell death, the target genes through which p53 halts the cell cycle have diversified. Indeed, p53 contributes to genome maintenance to a large part by allowing time for the DNA-repair machineries to remove the lesions before cell proliferation resumes. When DNA damage is present before the entry into S phase, p53 halts the cell cycle at the G₁ phase in part by transcriptionally inducing the cyclin-dependent kinase inhibitor *cdkn1a*, also known as p21 (el-Deiry et al. 1993). In nematodes, the p21 homolog *cki-1* is dispensable for the DNA-damage response as it specifically halts the cell cycle to allow differentiation of cells during unperturbed development (Buck et al. 2009).

During the time the cell cycle is halted, the highly specialized DNA-repair machineries pursue the damage removal. In addition to the well-defined role of p53 in regulating the cell cycle under the influence of DNA damage, p53 has also been directly implicated in the regulation of and participation in various DNA-repair pathways.

MULTITASKING FOR GENOME MAINTENANCE: P53 IN DNA REPAIR

Cells can revert the large variety of DNA lesions that are induced by endogenous and exogenous genotoxic attacks through a variety of sophisticated DNA-repair machineries, many of which somehow involve p53. Nucleotide excision repair (NER) removes a variety of helix-distorting lesions such as typically induced by UV irradiation, whereas base excision repair (BER) targets oxidative base modifications. Mismatch repair (MMR) scans for nucleotides that have been erroneously inserted during replication. DNA DSBs that are typically induced by IR

are resolved either by nonhomologous end joining (NHEJ) or by homologous recombination (HR), whereas RECQ helicases assume various roles in genome maintenance during recombination repair and replication.

Functions of p53 in Nucleotide Excision Repair

It has been known for more than 20 years that p53 has important roles in the repair of UV-induced DNA damage, both via *trans*-activation and *trans*-repression activities (transcriptional regulation) and via activities not directly associated with gene regulation. Hinting at a role for p53 in DNA repair, studies showed that p53 has both sequence-dependent and sequence-independent DNA-binding activities and that it may be involved in recognizing structures associated with DNA damage (Lee et al. 1995; Liu and Kulesz-Martin 2001). Perhaps the earliest connection between p53 and NER came from the work of Smith and colleagues when they showed that human cell lines with disrupted p53 function (either via a dominant negative mutation or expression of the human papillomavirus E6 oncoprotein) showed significant losses of fitness and survival after UV irradiation (Smith et al. 1995). Importantly, this study presented both *in vivo* and *in vitro* functions for p53. First, the investigators showed the *in vivo* importance of p53 using host-cell-reactivation experiments, which correlated with cell survival, as shown by clonogenic assays. They further showed that extracts from the same p53-defective cells were defective for tolerating UV-induced DNA damage. Although this study did not clarify whether the function of p53 in UV resistance was direct or via activities of p53-associated factors, it did lay an important foundation for the further characterization of the functions of p53 in NER (for a detailed review of NER, see Marteijn et al. 2014).

Several studies, which followed quite quickly, assigned the requirement for p53 in the survival of UV-induced DNA damage more specifically to the NER pathway. Two important studies from Phil Hanawalt's group revealed that p53 was important for the regulation

of global genome NER (GG-NER), but largely dispensable for transcription-coupled NER (TC-NER). In the first study, Ford and Hanawalt examined the functions of p53 in p53 heterozygous and homozygous Li–Fraumeni syndrome fibroblasts (Ford and Hanawalt 1995). Specifically, they showed that homozygous p53 mutant fibroblasts, which had spontaneously lost the wild-type p53 allele during culturing of p53 heterozygous lines (Yin et al. 1992), were defective for the removal of CPDs from overall genomic DNA compared with their heterozygous progenitors, suggesting a loss of GG-NER. In contrast, the homozygous cells remained proficient for TC-NER, the preferential removal of DNA damage from actively transcribed strands. They followed up and confirmed these findings by directly examining lesion repair using antibodies specific for CPDs and 6-4PPs (Ford and Hanawalt 1997). In a 1996 study, Mirzayans and colleagues (Mirzayans et al. 1996) independently confirmed a function for p53 in UV resistance in different cell lines and using different techniques from those of Ford and Hanawalt (1995). Their combined results showed that p53 was involved in repair mediated by DNA polymerases δ and ϵ ; however, in contrast to the results from the Hanawalt group, p53 seemed to be important for both GG-NER and TC-NER. Perhaps an even more direct connection between p53 and NER was provided by Wang and colleagues (Wang et al. 1995) when they showed that p53 can bind to several components of the NER pathway including XPC, XBP, and CSB.

The literature cited above shows a division on the question of whether p53 is involved only in GG-NER or whether it also participates in TC-NER. Consistent results have generally confirmed that p53 is important in the GG-NER pathway, so the controversy mostly surrounds its involvement in TC-NER. Clouding the issue even further, three later studies from Altaf Wani's group provided additional evidence that p53 is primarily involved in GG-NER, contradicting the results of Mirzayans et al. (1996) and agreeing with the earlier results from the Hanawalt group (Wani et al. 2000; 2002; Zhu et al. 2000). Can these contradictions be reconciled?

A.B. Williams and B. Schumacher

One possible explanation is that the discrepancy may stem from the type of UV source used for the irradiation (Sengupta and Harris 2005). This explanation is based on the observation that loss of p53 reduces TC-NER after exposure to broad-spectrum UV (290–324 nm), but not after irradiation with narrow-band UV (254 nm), despite a universal requirement for efficient GG-NER (Mathonnet et al. 2003). Interestingly, because 254 nm UV is almost non-existent in the spectrum of light reaching Earth from the Sun, p53 is likely part of the response to natural damage in both the transcribed and nontranscribed DNA strands.

These early studies clearly placed p53 in the NER pathway; however, they provided limited insight into whether the requirement for p53 in NER was via its *trans*-activation activity, or whether it directly acts in DNA-associated transactions during repair—in fact, p53 seems to act via both mechanisms. The involvement of p53 as a transcriptional regulatory in NER seems to be limited, as its only known relevant regulatory targets are the genes encoding the DDB2 protein (*p48*) and the XPC protein (*XPC*) (Hwang et al. 1999; Adimoolam and Ford 2002; Hastak et al. 2012). DDB2 associates with its binding partner DDB1 to form the UV-DDB heterodimer, which in turn binds to 6-PPs and CPDs to help recruit XPC during the early steps in NER (reviewed in Sugawara 2010). After UV-induced DNA damage, activated p53 induces the expression of *p48* and *XPC*, thus increasing the cell's capacity to locate and target DNA damage for repair. At least two observations support the *trans* requirement for p53 in regulating NER. First, endogenous expression of DDB2 in p53-deficient cells improves the efficiency of GG-NER (Fitch et al. 2003b). Second, XPC and DDB2 are recruited to sites of DNA damage, whereas p53 is not (Fitch et al. 2003a).

p53 may be most commonly associated with gene regulation at the transcriptional level, typically functioning as a transcriptional activator; thus, its function in regulating NER components transcriptionally is not surprising. In contrast, that p53 also appears to have functions in NER (and other DNA-repair pathways discussed below) independent of its transcription-

al role were perhaps more unexpected. Two transcription-independent functions for p53 in NER have been reported: (1) modulation of the helicase activities of XPB and XPD (Wang et al. 1995; Léveillard et al. 1996), and (2) modulation of chromatin accessibility (Rubbi and Milner 2003). The GG- and TC-NER subpathways converge on the common repair pathway with the local relaxation of the DNA by the multimeric protein TFIIH via the helicase activity of its XPB and XPD subunits. At least in vitro, XPB and XPD can interact with p53 leading to a decrease in their helicase activity. Because TFIIH plays a central role in NER, it is likely that these changes could influence its function, although the details remain to be worked out. The chromatin relaxation function for p53 is also spatially and temporally associated with TFIIH during NER. Following the recognition of a lesion by TC-NER branch, the chromatin is relaxed throughout the genome. Rubbi and colleagues hypothesized that this global relaxation leads to enhanced global lesion detection. This activity seems to be via p53-dependent recruitment of the p300 histone acetylase to damage sites where it acetylates the histone H3 subunit. In this way, p53 may generally increase lesion detection across the entire genome making an additional contribution to the maintenance of genome stability.

Finally, a function for p53 in the regulation of NER during chronic exposure to the potent genotoxin aflatoxin B₁ (AFB₁) has recently been described. In p53-proficient mice, dietary exposure to AFB₁ led to an increase in NER activity as measured by an in vitro assay (Mulder et al. 2014). This up-regulation of NER was eliminated in p53 haploinsufficient mice and was independent of the levels of the NER proteins XPA and XPB. The mechanism for this effect is yet to be elucidated.

Functions of p53 in Base Excision Repair

The reported roles of p53 in the BER pathway reveal even more the diverse repertoire of functions for p53. As in NER, p53 has both transcription-dependent and transcription-independent functions in BER. Apurinic and

aprimidinic (AP) endonucleases are key players in BER that function downstream from the DNA glycosylases (such as OGG1) during the removal of damaged bases and the subsequent repair of the resulting AP sites. Interestingly, studies have shown several different connections between AP endonucleases and p53, the earliest of which were described in studies that showed an interaction between the bifunctional AP endonuclease APE1/Ref-1 and p53 (Jayaraman et al. 1997; Gaiddon et al. 1999). Jayaraman et al. made the initial observation that p53 was regulated by APE1/Ref-1 via redox-dependent and -independent pathways. Subsequently, Gaiddon et al. showed that Ref-1 enhances p53 DNA binding in vitro and that the effects of this regulation can be mirrored in vivo. Through these interactions, APE1/Ref-1 modulated the *trans*-activation and proapoptotic functions of p53. A 2005 study revealed that the function of APE1/Ref-1 was to promote the tetramerization of p53 (Hanson et al. 2005). Interestingly, only in 2014 was it discovered that APE1/Ref-1 can also modulate the DNA-binding activity of mutant p53 through a redox-dependent mechanism (Cun et al. 2014). A further connection between p53 and APE1/Ref-1 was reported by Seo and colleagues when they showed that selenomethionine (SeMet) can activate p53 in a Ref-1-dependent manner (Seo et al. 2002b). These findings established a connection between the dietary nutrient selenium and the regulation of DNA repair. In fact, selenomethionine showed some protective effect against IR (Jeong et al. 2009). The effects of selenomethionine on p53 and BER have been extensively studied because selenomethionine can be used to stimulate p53 and its genome protective functions independent of genotoxic effects, thus supporting its use as a chemotherapeutic agent (for example, see Jung et al. 2013). Finally, in addition to its transcription-independent interaction with APE1, p53 also seems to directly repress transcription of the *APE1* gene (Zaky et al. 2008). This role for p53 is particularly interesting because it may seem contradictory—why would cells repress a DNA-repair gene when facing DNA damage? In fact, such a function could contribute to the

p53 in the DNA-Damage-Repair Process

tumor suppressor function of p53 as p53-dependent down-regulation of DNA-repair activity could skew the DNA-damage response in the direction of apoptosis to clear highly damaged genomes.

The studies above show that BER can influence the activity of p53, but the question remains whether or not p53 can also regulate BER? The first bona fide example of a function of p53 in BER came from Varda Rotter's group when they showed that cell extracts overproducing p53 had increased BER activity in vitro (Offer et al. 1999). Follow-up work indicated that this connection between p53 and BER was independent of the transcriptional activity of p53 because the p53 transactivation-deficient protein (p53-22-23) was actually more effective in controlling BER than wild-type p53 (Offer et al. 2001a). The investigators concluded that the transcription-independent function of p53 could represent a more acute response to DNA damage. This conclusion was supported by work in which they examined how the amount of DNA damage influences this pathway (Offer et al. 2002). The data in this study revealed a dose-dependent component of this regulation: on low doses of DNA-damaging agents (γ -irradiation or cisplatin), there was an immediate increase in BER activity; in contrast, higher doses led to a reduction in BER and p53-dependent apoptosis. Consistent with this biological function, they showed that p53 can enhance BER during G₀-G₁ stages of the cell cycle while reducing BER and inducing apoptosis during G₂-M; thus, p53 seems to act as a modulator of BER activity throughout the cell cycle (Offer et al. 2001b).

That p53 can functionally influence BER was further shown by its ability to regulate the 3-methyladenine (3-MeAde) DNA glycosylase. Zurer et al. (another study from the Rotter group) showed that nitric oxide treatment increases the activity of 3-MeAde (as expected because 3-MeAde is the first enzyme in the BER pathway) (Zurer et al. 2004). Wild-type p53 suppressed this increase by repressing the glycosylase mRNA, thus operating as a transcriptional regulator. Interestingly, the activity of the AP endonuclease protein was not altered under these conditions. In the absence of p53, elevated

A.B. Williams and B. Schumacher

glycosylase activity could lead to an increased number of AP sites and, without a concomitant increase the AP endonuclease activity to repair them, this imbalance could then lead to genome instability because of weakened DNA repair. Together, these observations suggest that this regulatory effect of p53 on a BER component could limit the mutagenic effects of some genotoxins.

Incidentally, some work has showed that p53 can also regulate the expression of two additional BER genes at the transcriptional level: *OGG1* (the gene for 8-oxoguanine glycosylase) (Chatterjee et al. 2006) and *MUTYH*, which encodes an adenine DNA glycosylase (Oka et al. 2014). The interaction between p53 and *MUTYH* is particularly interesting as research on *MUTY* has intensified in recent years because of its role in hereditary colorectal cancer (for a review, see de Oliveira et al. 2014).

More recent relationships between carcinogen exposure and p53 have also been reported. Hamann et al. showed that, after cadmium exposure, p53 exerts effects on BER by regulating *OGG1* and *APE1* (Hamann et al. 2012); although p53 directly regulated the expression of *APE1*, it appeared to affect *OGG1* only indirectly. A function for p53 during chronic exposure to low doses of AFB₁ has also been reported (Mulder et al. 2015). Mulder et al. showed that BER activity was decreased in p53-proficient mouse livers, but was unchanged in p53-heterozygous knockouts. Notably, this effect is the opposite of what the same group reported for regulation of NER by p53 during AFB₁ exposure (above) (Mulder et al. 2014).

The above results show that p53 can certainly control various aspects of BER, but can the protein be placed directly at repair sites? Direct protein–protein and protein–DNA interactions between p53 and several BER components seem to suggest so. Wild-type p53 was shown to enhance the activity of *OGG1* both in vitro and in vivo (Achanta and Huang 2004). When cells were exposed to the same levels of reactive oxygen species (ROS), wild-type p53 cells showed more rapid removal of the resulting lesions (8-oxoG) from the DNA compared with p53-defective cells. This enhancement occurred

when p53 was bound to DNA in association with *OGG1* and AP endonuclease, and it was hypothesized that p53 may stimulate the combined activities of *OGG1* and AP endonuclease.

DNA polymerase β (DNA pol β) is the main DNA polymerase involved in short patch BER and acts downstream from the glycosylase and AP endonuclease to insert the new complementary base. Zhou et al. again showed that p53 can stimulate BER both in vitro and in vivo and that this activity correlates with the amount of p53. The novel aspect of this study was that they also showed that this effect depended on the ability of p53 to directly interact with DNA pol β because amino-terminal mutant forms of p53 that do not interact with DNA pol β fail to stimulate BER (Zhou et al. 2001) (subsequent work from the same group further corroborated a function for p53 in DNA replication [Zhou and Prives 2003]). One suggestion for the basis for this effect is that the interaction between DNA pol β and p53 might affect the stability of the polymerase because DNA pol β levels are drastically decreased in p53-deficient cells (Seo et al. 2002a). In this case, a direct interaction between p53 and a BER component could serve a critical function in ensuring proper BER function.

Functions of p53 in Mismatch Repair

Of the trifecta of classical DNA-repair pathways, p53 probably has the least known interactions with DNA MMR (Fig. 1), although that is not to say that the interactions are unimportant. The relationship between p53 and MMR seems to be centered on the MMR core component MSH2; however, it is important to note that MSH2 also functions to some extent in NER, HR, and BER, so p53-dependent effects on MSH2 may also influence other DNA-repair pathways.

Connections between p53 and MMR have been made in various systems and several examples demonstrate a role for MMR proteins in influencing p53-related processes. For example, Cranston et al. showed that p53 and MMR function synergistically in mice, as *Msh2*^{−/−} p53^{−/−} females arrested as embryos and, although the males survived, they quickly developed tumors relative to the single-mutant ani-

Figure 1. Examples of p53 interactions with DNA-repair pathways. (A–C) Simplified representations of canonical DNA-repair pathways: nucleotide excision repair (NER), base excision repair (BER), and mismatch repair (MMR). Factors with transcription-related interactions are highlighted in orange and factors with nontranscriptional interactions are highlighted in blue. Note that OGG1 has both transcription-dependent and -independent interactions with p53 during base excision repair. Red arrows indicate regulatory effects on p53.

mals (Cranston et al. 1997). Around the same time, Lin et al. showed that, in an MMR-defective colon carcinoma cell line, MMR and p53 can work together to modulate the cell's sensitivity to the genotoxic effects of cisplatin (Lin et al. 2001).

p53 has also been linked to the DNA-damage-response signaling pathway as the MMR proteins hMutL and PMS1/2 (components of the MMR pathway) are stabilized by the DNA-damage-response checkpoint protein ATM after DNA damage, leading to an increase in p53 activation (Luo et al. 2004). Interestingly, the MSH2–MSH6 complex can, at least in vitro, enhance the binding of p53 to DNA substrates with topological distortions, and this activity depends on the phosphorylation state of p53 (Subramanian and Griffith 2002, 2005). In one study, p53 and MSH2 were shown to colocalize to early recombination intermediates, suggesting that p53 is linked to recombination by a non-MMR function of MSH2 (Zink et al. 2002). More recently, p53 signaling was shown to be suppressed in MSH2-deficient cells (Pabla et al. 2011), and MUTS3 was found to be a powerful effector of p53-dependent tumorigenesis (van Oers et al. 2014).

The transcriptional function of p53 may also regulate MMR. p53, along with the transcription factor c-Jun, bind to motifs in the promoter region of *hMSH2* (Scherer et al. 1996, 2000). The biological effect of this binding is an up-regulation of *hMSH2* after UV exposure.

Finally, clinically relevant connections between MMR and p53 are abundant in the literature; however, in most cases, little mechanistic information exists to explain the observations. Nevertheless, for just a few interesting examples, see Martinez et al. (2009), Schröer et al. (2009), Haghighi et al. (2014), and Shen et al. (2014).

Functions of p53 in DNA Double-Strand Break Repair and Recombination

DNA DSBs are repaired by two pathways, depending on the stage of the cell cycle: NHEJ is active throughout the cell cycle, but especially important in G₁ (Deriano and Roth 2013) and HR, which is most active during late S and G₂ (Jasin and Rothstein 2013). Although HR-dependent repair is largely error free, NHEJ can be inaccurate, leading to genomic instability, although opinions are shifting in both of these

A.B. Williams and B. Schumacher

areas (Bétermier et al. 2014; Guirouilh-Barbat et al. 2014). p53 has diverse roles in each of these pathways and each pathway will be discussed individually here.

p53 in Nonhomologous End Joining

Under some conditions, p53 functions seem to intersect with NHEJ, although the biological outcome seems to be via effects on apoptosis. For example, DSBs are maintained in mice defective for XRCC4 and DNA ligase IV (thus lacking NHEJ), leading to p53-dependent apoptosis and embryonic lethality (Gao et al. 1998, 2000; Frank et al. 2000). In this background, loss of p53 can rescue the embryonic lethality (although probably at the expense of genome stability).

Mice deficient for p53 and NHEJ were reported to develop a number of pathologies including progenitor B-cell lymphomas (Guidos et al. 1996; Nacht et al. 1996; Vanasse et al. 1999; Frank et al. 2000; Gao et al. 2000; Difilippantonio et al. 2002; Gladdy et al. 2003).

Subsequently, work from Fred Alt's group showed that the Artemis endonuclease could, in cooperation with p53, suppress the development of progenitor B-cell lymphomas (Rooney et al. 2004). Artemis also has an additional DNA-repair-independent function in p53 regulation. In U2-OS cells depleted for Artemis, p53 accumulates leading to cell-cycle arrest and apoptosis (Zhang et al. 2009); thus, at least one component of NHEJ can also exert a regulatory effect on p53.

Several other connections have been made between p53 and the repair of DSBs apparently by NHEJ, although these connections may be more circumstantial (Fig. 2). For example, two studies with I-SceI systems that facilitate an exogenous endonuclease to produce DSBs at specific sites have suggested a connection between p53 and NHEJ. Through the use of I-SceI-recognition sites, functions for p53 outside of DSB repair can be largely excluded, as DSBs can be specifically induced without the use of other genotoxic agents, which in many cases leads to

Figure 2. Examples of p53 interactions with double-strand break repair pathways (left) and p53 checkpoint signaling (right). (A,B) Simplified representations of double-strand break repair via homologous recombination (HR) and nonhomologous end joining (NHEJ). (C) Simplified representation of p53 signaling at double-strand breaks. Factors with transcription-related interactions are highlighted in orange and factors with nontranscriptional interactions are highlighted in blue. Note that RAD51 has both transcription-dependent and -independent interactions with p53 during base excision repair. Red labels and red arrows indicate regulatory effects on p53.

multiple types of the DNA damage. In the first study, wild-type p53 inhibited NHEJ that used microhomologies near the cut site (Akyüz et al. 2002). In the second study, pharmacological inhibition of p53 by pifithrin- α had little effect on overall end joining; however, high-fidelity end joining was diminished (Lin et al. 2003). This finding suggests another genome-protective function for p53: to minimize genome instability caused by low-fidelity NHEJ.

Of the two pathways for DSB repair, the roles of p53 in NHEJ remain the most nebulous. What is clear is that p53 has several genetic interactions with components of the NHEJ pathway that are manifested by downstream effects on cellular survival and cell-cycle control or effects on DNA repair; to date, the molecular mechanisms of these interactions remain poorly or entirely not understood.

p53 in Homologous Recombination

The roles of p53 in HR are clearer than those in NHEJ and, in fact, p53 has been shown to have both *trans*-activation-dependent and -independent functions in regulating HR, independent of its functions in cell-cycle checkpoint control (this separation of functions was first reported by Willers et al. 2000). To date, most of the roles of p53 in HR are independent of its transcriptional activity (see below); however, several studies have revealed what may turn out to be important *trans*-activation functions for p53 in the regulation of HR. After many experiments examining the role of p53 in the repair of I-SceI DSBs (including work with transactivation-defective mutants) Rieckmann et al. present data showing that p53 regulates HR-dependent repair of induced DSBs via its *trans*-activation function; however, they maintain that its role in HR repair of replication-associated DSBs is independent of its *trans*-activation function (Rieckmann et al. 2013). Further support that p53 can regulate DSB repair transcriptionally comes from several studies that showed direct interactions between p53 and the Rad51 promoter, with corresponding changes in *RAD51* expression (Hasselbach et al. 2005; Arias-Lopez et al. 2006; Fong et al. 2011). Most recently, Hine

et al. confirmed that p53 can directly regulate *RAD51*, although its contribution was small compared with other transcription factors (Hine et al. 2014). Finally, the p53 isoform $\Delta 133$ p53, which is expressed from an internal promoter in the p53 gene and is a regulatory target of full-length p53 itself, has also been shown to up-regulate several DNA-repair genes, including *RAD51* (Gong et al. 2015).

In addition to regulating the expression of Rad51, p53 also appears to modulate HR via direct interactions with the RAD51 and RAD54 proteins. The frequency of spontaneous and damage-induced HR between repetitive DNA sequences increases on p53 inhibition (Saintigny et al. 1999). A subsequent study several years later confirmed that this effect was because of a p53-RAD51 interaction by overexpressing a mutant RAD51 that was unable to interact with p53 (Linke et al. 2003). This overexpression resulted in a twofold to threefold increase in HR, similar to the earlier phenotype from p53 inhibition. This same study also reported an interaction between p53 and RAD54 via the carboxy-terminal domain of p53. The investigators conclude that p53 likely inhibits illegitimate recombination by inhibitory interactions with RAD51 and RAD54, suggesting yet another mechanism by which p53 could suppress genome instability. Although these studies clearly demonstrate that p53 can modulate HR, it has also been shown that interaction between RAD51 and p53 can stimulate the 5' to 3' exonuclease activity of p53 during the production of strand transfer intermediates; thus, RAD51 and p53 seem to affect each other bidirectionally.

Other studies have revealed functions for p53 in regulating HR that did not explicitly involve interaction with RAD51. Three studies from Lisa Wiesmüller's group are especially notable. First, they showed that even when the transactivation domain of p53 was fully inactivated, p53 could still regulate HR (interestingly, this finding is in stark contrast to the findings of Rieckmann et al. discussed above) (Boehden et al. 2003). Next, they showed that p53 can both repress and stimulate HR depending on the substrate sequence and that such effects

A.B. Williams and B. Schumacher

may be influenced by interactions with DNA topoisomerase I (Boehden et al. 2004). In a later study, they showed that p53 stimulates HR in the ribosomal gene cluster repeat, which they speculate represents a function for p53 in regulating the integrity of rDNA sequences (Boehden et al. 2005). Taken together, the investigators argue that p53 promotes genome stability through lesion-specific interactions with topoisomerase I, global repression of mutant genetic strand exchange, and by promoting directed recombination events to maintain rDNA.

p53 also seems to play a role in regulating replication-related recombination that is tightly linked to the ATM/ATR checkpoint kinases. When replication inhibitors or DNA cross-linking agents are used to induce replication stress leading to stretches of single-strand DNA, p53 suppresses HR (Romanova et al. 2004). Interestingly, this activity requires phosphorylation of p53 and a direct interaction with the ssDNA binding protein RPA. This phenotype was further clarified by Sirbu et al. when they showed that this antirecombinogenic activity requires that phosphorylation of p53 by ATR (Sirbu et al. 2011). Through this mechanism, p53 can modulate HR frequency associated with the S phase replication stress checkpoint, without altering the cell's capacity to use HR for repair of exogenously generated DSBs. A later study showed that the checkpoint components ATM and ATR, along with the DNA-dependent protein kinase (DNA-PK), can modulate the physical interaction between p53 and RPA (Serrano et al. 2013). On DNA damage, p53 is phosphorylated by DNA-PK and RPA is phosphorylated by both ATM and ATR at two sites. Only together can these phosphorylation events disrupt the p53-RPA interaction, liberating both proteins to carry out their DNA-damage-associated functions. This pathway also reveals some cross talk between p53's regulation of HR and NHEJ as DNA-PK is also a central component of the NHEJ pathway.

p53 and RecQ Helicases

The human genome encodes five DNA helicases belonging to the RecQ helicase family (Croteau

et al. 2014). Each of the helicases has important responsibilities in the maintenance of genome stability via specific recombination functions. Deficiencies in three of these helicases cause well-characterized, although still not entirely understood, heritable human diseases: BLM (Bloom syndrome), WRN (Werner syndrome), and RECQL4 (Rothmund–Thompson syndrome, and others) (Monnat 2010). The diseases cause various phenotypes, especially developmental and immunological defects, genome instability, and increased cancer risk. WRN additionally results in premature aging. Interestingly, interactions between these three disease-related helicases and p53 have been identified.

BLM causes a predisposition to many different types of cancers, including epithelial tumors (breast, colon, lung), blood cell cancers (leukemias, lymphomas), connective tissue tumors (sarcomas), and several embryonic tumors. The relationship between BLM and p53 was established when it was shown that changes in p53 levels after DNA damage differed depending on BLM status (Collister et al. 1998). Garkavtsev et al. later showed that p53 and BLM directly interact and that they act together to control transcription and cellular growth (Garkavtsev et al. 2001). BLM has also been shown to influence HR at stalled replication forks by controlling the localization of p53 (Sengupta et al. 2003) and to regulate Holliday junction processing (Yang et al. 2002). In addition, BLM can affect apoptosis (Wang et al. 2001) and interacts with p53 in many clinically important contexts (for example, see Wirtenberger et al. 2006; Babbe et al. 2009; Kaneko et al. 2011).

As noted above, an important clinical feature of WRN is premature aging and, like BLM, WRN deficiency also results in an elevated, although more limited, cancer risk. Several studies have identified important connections between WRN activity and p53. Like BLM, WRN is also involved in p53-dependent apoptosis (Spillare et al. 1999). WRN and p53 interact physically and this interaction may affect the *trans*-activation functions of p53 (Blander et al. 1999). WRN-deficient cells do not induce the *p53* gene after DNA damage and this func-

tion may at least partially explain the cancer predisposition in WRN patients (Blander et al. 2000). Some insight into the molecular underpinning of the premature aging in WRN patients came from a mouse model that showed that WRN deficiency can accelerate aging in the absence of p53 (Lombard et al. 2000). Later work showed that p53 can also modulate the biochemical activities of WRN (Brosh et al. 2001) and that it can regulate WRN's Holliday junction-processing activity (Yang et al. 2002).

Interactions between RECQL4 and p53 have been more recently reported. RECQL4 has a DNA-damage-independent function related to p53, as it is important for the trafficking of p53 to mitochondria in normal, unstressed human cells (De et al. 2012). Interestingly, p53 itself represses the expression of *RECQL4* (Sengupta et al. 2005), perhaps serving to control its own cellular localization, although this interpretation is only speculative. The relationship between p53 and RECQL4 is an active area of research and new results are likely to emerge (for some recent findings, see Gupta et al. 2014 and Lu et al. 2015).

CONCLUDING REMARKS

With the central importance of p53 in controlling genome instability-driven cancer development, it might not be surprising that p53 controls DNA-damage checkpoints and impacts the activity of various DNA-repair systems. Given the many ways through which p53 guards the genome, it remains a major challenge to mechanistically dissect the distinct functions of p53. Studies in various model systems will continuously enrich the understanding of the physiological roles of p53 also in the context of genome evolution. Cytological and biochemical studies in the context of living organisms are likely to reveal yet additional functions of p53 in responding to genome instability.

ACKNOWLEDGMENTS

B. Schumacher acknowledges financial support from the Deutsche Forschungsgemeinschaft (CECAD, SFB 829, SFB 670, and KFO 286), the European Research Council (ERC

Starting Grant 260383), Marie Curie (FP7 ITN CodeAge 316354, aDdRes 316390, MARRIAGE 316964, and ERG 239330), the Deutsche Krebshilfe (109453), and the Bundesministerium für Forschung und Bildung (Sybacol FKZ0315893A-B).

REFERENCES

- Achanta G, Huang P. 2004. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. *Cancer Res* **64**: 6233–6239.
- Adimoolam S, Ford JM. 2002. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. *Proc Natl Acad Sci* **99**: 12985–12990.
- Akyüz N, Boehden GS, Süsse S, Rimek A, Preuss U, Scheidtmann K-H, Wiesmüller L. 2002. DNA substrate dependence of p53-mediated regulation of double-strand break repair. *Mol Cell Biol* **22**: 6306–6317.
- Arias-Lopez C, Lazaro-Trueba I, Kerr P, Lord CJ, Dexter T, Iravani M, Ashworth A, Silva A. 2006. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. *EMBO Rep* **7**: 219–224.
- Babbe H, McMenamin J, Hobeika E, Wang J, Rodig SJ, Reth M, Leder P. 2009. Genomic instability resulting from Blm deficiency compromises development, maintenance, and function of the B cell lineage. *J Immunol* **182**: 347–360.
- Bétermier M, Bertrand P, Lopez BS. 2014. Is non-homologous end-joining really an inherently error-prone process? *PLoS Genet* **10**: e1004086.
- Blander G, Kipnis J, Leal JF, Yu CE, Schellenberg GD, Oren M. 1999. Physical and functional interaction between p53 and the Werner's syndrome protein. *J Biol Chem* **274**: 29463–29469.
- Blander G, Zalle N, Leal JF, Bar-Or RL, Yu CE, Oren M. 2000. The Werner syndrome protein contributes to induction of p53 by DNA damage. *FASEB J* **14**: 2138–2140.
- Boehden GS, Akyüz N, Roemer K, Wiesmüller L. 2003. p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair. *Oncogene* **22**: 4111–4117.
- Boehden GS, Restle A, Marschalek R, Stocking C, Wiesmüller L. 2004. Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53. *Carcinogenesis* **25**: 1305–1313.
- Boehden GS, Baumann C, Siehler S, Wiesmüller L. 2005. Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat. *Oncogene* **24**: 4183–4192.
- Brosh RM, Karmakar P, Sommers JA, Yang Q, Wang XW, Spillare EA, Harris CC, Bohr VA. 2001. p53 Modulates the exonuclease activity of Werner syndrome protein. *J Biol Chem* **276**: 35093–35102.
- Buck SH, Chiu D, Saito RM. 2009. The cyclin-dependent kinase inhibitors, cki-1 and cki-2, act in overlapping but distinct pathways to control cell cycle quiescence during *C. elegans* development. *Cell Cycle* **8**: 2613–2620.

A.B. Williams and B. Schumacher

- Chatterjee A, Mambo E, Osada M, Upadhyay S, Sidransky D. 2006. The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity. *FASEB J* **20**: 112–114.
- Collister M, Lane DP, Kuehl BL. 1998. Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts. *Carcinogenesis* **19**: 2115–2120.
- Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R. 1997. Female embryonic lethality in mice nullizygous for both Msh2 and p53. *Nat Genet* **17**: 114–118.
- Croteau DL, Popuri V, Opreko PL, Bohr VA. 2014. Human RecQ helicases in DNA repair, recombination, and replication. *Annu Rev Biochem* **83**: 519–552.
- Cun Y, Dai N, Li M, Xiong C, Zhang Q, Sui J, Qian C, Wang D. 2014. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner. *Oncol Rep* **31**: 901–909.
- De S, Kumari J, Mudgal R, Modi P, Gupta S, Futami K, Goto H, Lindor NM, Furuichi Y, Mohanty D, et al. 2012. RECQL4 is essential for the transport of p53 to mitochondria in normal human cells in the absence of exogenous stress. *J Cell Sci* **125**: 2509–2522.
- de Oliveira AHS, da Silva AE, de Oliveira IM, Henriques JAP, Agnez-Lima LF. 2014. MutY-glycosylase: An overview on mutagenesis and activities beyond the GO system. *Mutat Res* **769**: 119–131.
- Deriano L, Roth DB. 2013. Modernizing the nonhomologous end-joining repertoire: Alternative and classical NHEJ share the stage. *Annu Rev Genet* **47**: 433–455.
- Derry WB, Putzke AP, Rothman JH. 2001. *Caenorhabditis elegans* p53: Role in apoptosis, meiosis, and stress resistance. *Science* **294**: 591–595.
- Derry WB, Bierings R, van Iersel M, Satkunendran T, Reinke V, Rothman JH. 2007. Regulation of developmental rate and germ cell proliferation in *Caenorhabditis elegans* by the p53 gene network. *Cell Death Differ* **14**: 662–670.
- Difilippantonio MJ, Petersen S, Chen HT, Johnson R, Jasini M, Kanaar R, Ried T, Nussenzweig A. 2002. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. *J Exp Med* **196**: 469–480.
- el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. *Cell* **75**: 817–825.
- Fitch ME, Cross IV, Ford JM. 2003a. p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. *Carcinogenesis* **24**: 843–850.
- Fitch ME, Cross IV, Turner SJ, Adimoolam S, Lin CX, Williams KG, Ford JM. 2003b. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. *DNA Repair* **2**: 819–826.
- Fong V, Osterbur M, Capella C, Kim Y-E, Hine C, Gorbunova V, Seluanov A, Dewhurst S. 2011. Adenoviral vector driven by a minimal Rad51 promoter is selective for p53-deficient tumor cells. *PLoS ONE* **6**: e28714.
- Ford JM, Hanawalt PC. 1995. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. *Proc Natl Acad Sci* **92**: 8876–8880.
- Ford JM, Hanawalt PC. 1997. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. *J Biol Chem* **272**: 28073–28080.
- Frank KM, Sharpless NE, Gao Y, Sekiguchi JM, Ferguson DO, Zhu C, Manis JP, Horner J, DePinho RA, Alt FW. 2000. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. *Mol Cell* **5**: 993–1002.
- Gaididon C, Moorthy NC, Prives C. 1999. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. *EMBO J* **18**: 5609–5621.
- Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ, Sekiguchi JM, Rathbun GA, Swat W, Wang J, et al. 1998. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. *Cell* **95**: 891–902.
- Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM, Chaudhuri J, Horner J, DePinho RA, Alt FW. 2000. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. *Nature* **404**: 897–900.
- Garkavtsev IV, Kley N, Grigorian IA, Gudkov AV. 2001. The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control. *Oncogene* **20**: 8276–8280.
- Gartner A, Milstein S, Ahmed S, Hodgkin J, Hengartner MO. 2000. A conserved checkpoint pathway mediates DNA damage-induced apoptosis and cell cycle arrest in *C. elegans*. *Mol Cell* **5**: 435–443.
- Gaddy RA, Taylor MD, Williams CJ, Grandal I, Karaskova J, Squire JA, Rutka JT, Guidos CJ, Danska JS. 2003. The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. *Cancer Cell* **3**: 37–50.
- Gong L, Gong H, Pan X, Chang C, Ou Z, Ye S, Yin L, Yang L, Tao T, Zhang Z, et al. 2015. p53 isoform $\Delta 113p53/\Delta 133p53$ promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. *Cell Res* **25**: 351–369.
- Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MT, Danska JS. 1996. V(D)J recombination activates a p53-dependent DNA damage checkpoint in *scid* lymphocyte precursors. *Genes Dev* **10**: 2038–2054.
- Guiouilh-Barbat J, Lambert S, Bertrand P, Lopez BS. 2014. Is homologous recombination really an error-free process? *Front Genet* **5**: 175.
- Gupta S, De S, Srivastava V, Hussain M, Kumari J, Muniyappa K, Sengupta S. 2014. RECQL4 and p53 potentiate the activity of polymerase γ and maintain the integrity of the human mitochondrial genome. *Carcinogenesis* **35**: 34–45.
- Haghighi MM, Aghagholzadeh P, Zadeh SM, Molaei M, Zali MR, Radpour R. 2014. Telomere shortening: A biological marker of sporadic colorectal cancer with normal expression of p53 and mismatch repair proteins. *Genet Test Mol Biomarkers* **18**: 236–244.

- Hamann I, König C, Richter C, Jahnke G, Hartwig A. 2012. Impact of cadmium on hOGG1 and APE1 as a function of the cellular p53 status. *Mutat Res* **736**: 56–63.
- Hanson S, Kim E, Deppert W. 2005. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. *Oncogene* **24**: 1641–1647.
- Hasselbach L, Haase S, Fischer D, Kolberg HC, Stürzbecher HW. 2005. Characterisation of the promoter region of the human DNA-repair gene Rad51. *Eur J Gynaecol Oncol* **26**: 589–598.
- Hastak K, Adimoolam S, Trinklein ND, Myers RM, Ford JM. 2012. Identification of a functional in vivo p53 response element in the coding sequence of the xeroderma pigmentosum group C gene. *Genes Cancer* **3**: 131–140.
- Hine CM, Li H, Xie L, Mao Z, Seluanov A, Gorbunova V. 2014. Regulation of Rad51 promoter. *Cell Cycle* **13**: 2038–2045.
- Hofmann ER, Milstein S, Boulton SJ, Ye M, Hofmann JJ, Stergiou L, Gartner A, Vidal M, Hengartner MO. 2002. *Caenorhabditis elegans* HUS-1 is a DNA damage checkpoint protein required for genome stability and EGL-1-mediated apoptosis. *Curr Biol* **12**: 1908–1918.
- Hwang BJ, Ford JM, Hanawalt PC, Chu G. 1999. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. *Proc Natl Acad Sci* **96**: 424–428.
- Jasin M, Rothstein R. 2013. Repair of strand breaks by homologous recombination. *Cold Spring Harb Perspect Biol* **5**: a012740.
- Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C. 1997. Identification of redox/repair protein Ref-1 as a potent activator of p53. *Genes Dev* **11**: 558–570.
- Jeong SW, Jung HJ, Rahman MM, Hwang JN, Seo YR. 2009. Protective effects of selenomethionine against ionizing radiation under the modulation of p53 tumor suppressor. *J Med Food* **12**: 389–393.
- Jung HJ, Kim HL, Kim YJ, Weon J-I, Seo YR. 2013. A novel chemopreventive mechanism of selenomethionine: Enhancement of APE1 enzyme activity via a Gadd45a, PCNA and APE1 protein complex that regulates p53-mediated base excision repair. *Oncol Rep* **30**: 1581–1586.
- Kaneko H, Fukao T, Kasahara K, Yamada T, Kondo N. 2011. Augmented cell death with Bloom syndrome helicase deficiency. *Mol Med Rep* **4**: 607–609.
- Lee S, Elenbaas B, Levine A, Griffith J. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. *Cell* **81**: 1013–1020.
- Léveillard T, Andera L, Bissonnette N, Schaeffer L, Bracco L, Egly JM, Waslyk B. 1996. Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. *EMBO J* **15**: 1615–1624.
- Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. 2001. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. *Cancer Res* **61**: 1508–1516.
- Lin Y, Waldman BC, Waldman AS. 2003. Suppression of high-fidelity double-strand break repair in mammalian chromosomes by pifithrin- α , a chemical inhibitor of p53. *DNA Repair* **2**: 1–11.
- Linke SP, Sengupta S, Khobie N, Jeffries BA, Buchhop S, Miska S, Henning W, Pedoux R, Wang XW, Hofseth LJ, et al. 2003. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. *Cancer Res* **63**: 2596–2605.
- Liu Y, Kulesz-Martin M. 2001. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. *Carcinogenesis* **22**: 851–860.
- Lombard DB, Beard C, Johnson B, Marciniak RA, Dausman J, Bronson R, Buhlmann JE, Lipman R, Curry R, Sharpe A, et al. 2000. Mutations in the WRN gene in mice accelerate mortality in a p53-null background. *Mol Cell Biol* **20**: 3286–3291.
- Lu L, Harutyunyan K, Jin W, Wu J, Yang T, Chen Y, Joeng KS, Bae Y, Tao J, Dawson BC, et al. 2015. RECQL4 regulates p53 function in vivo during skeletogenesis. *J Bone Miner Res* **30**: 1077–1089.
- Luo Y, Lin F-T, Lin W-C. 2004. ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage. *Mol Cell Biol* **24**: 6430–6444.
- Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JHJ. 2014. Understanding nucleotide excision repair and its roles in cancer and ageing. *Nat Rev Mol Cell Biol* **15**: 465–481.
- Martinez P, Siegl-Cachedenier I, Flores JM, Blasco MA. 2009. MSH2 deficiency abolishes the anticancer and pro-ageing activity of short telomeres. *Ageing Cell* **8**: 2–17.
- Mathonnet G, Leger C, Desnoyers J, Drouin R, Therrien J-P, Drobetsky EA. 2003. UV wavelength-dependent regulation of transcription-coupled nucleotide excision repair in p53-deficient human cells. *Proc Natl Acad Sci* **100**: 7219–7224.
- Mirzayans R, Enns L, Dietrich K, Barley RDC, Paterson MC. 1996. Faulty DNA polymerase δ/ϵ -mediated excision repair in response to γ radiation or ultraviolet light in p53-deficient fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. *Carcinogenesis* **17**: 691–698.
- Monnat RJ. 2010. Human RECQ helicases: Roles in DNA metabolism, mutagenesis and cancer biology. *Semin Cancer Biol* **20**: 329–339.
- Mulder JE, Bondy GS, Mehta R, Massey TE. 2014. Up-regulation of nucleotide excision repair in mouse lung and liver following chronic exposure to aflatoxin B1 and its dependence on p53 genotype. *Toxicol Appl Pharmacol* **275**: 96–103.
- Mulder JE, Bondy GS, Mehta R, Massey TE. 2015. The impact of chronic Aflatoxin B1 exposure and p53 genotype on base excision repair in mouse lung and liver. *Mutat Res* **773**: 63–68.
- Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, Jacks T. 1996. Mutations in the p53 and SCID genes cooperate in tumorigenesis. *Genes Dev* **10**: 2055–2066.
- Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. 1999. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. *FEBS Lett* **450**: 197–204.

A.B. Williams and B. Schumacher

- Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V. 2001a. Structural and functional involvement of p53 in BER in vitro and in vivo. *Oncogene* **20**: 581–589.
- Offer H, Zurer I, Banfalvi G, Reha'k M, Falcovitz A, Milyavsky M, Goldfinger N, Rotter V. 2001b. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. *Cancer Res* **61**: 88–96.
- Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N, Rotter V. 2002. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. *Carcinogenesis* **23**: 1025–1032.
- Oka S, Leon J, Tsuchimoto D, Sakumi K, Nakabeppu Y. 2014. MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death. *Oncogenesis* **3**: e121.
- Pabla N, Ma Z, McIlhatton MA, Fishel R, Dong Z. 2011. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. *J Biol Chem* **286**: 10411–10418.
- Rieckmann T, Kriegs M, Nitsch L, Hoffer K, Rohaly G, Kocher S, Petersen C, Dikomey E, Dornreiter I, Dahm-Daphi J. 2013. p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation. *Oncogene* **32**: 968–975.
- Romanova IY, Willers H, Blagosklonny MV, Powell SN. 2004. The interaction of p53 with replication protein A mediates suppression of homologous recombination. *Oncogene* **23**: 9025–9033.
- Rooney S, Sekiguchi J, Whitlow S, Eckersdorff M, Manis JB, Lee C, Ferguson DO, Alt FW. 2004. Artemis and p53 cooperate to suppress oncogenic *N-myc* amplification in progenitor B cells. *Proc Natl Acad Sci* **101**: 2410–2415.
- Rubbi CP, Milner J. 2003. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. *EMBO J* **22**: 975–986.
- Saintigny Y, Rouillard D, Chaput B, Soussi T, Lopez BS. 1999. Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G₁ checkpoint. *Oncogene* **18**: 3553–3563.
- Scherer SJ, Seib T, Seitz G, Dooley S, Welter C. 1996. Isolation and characterization of the human mismatch repair gene hMSH2 promoter region. *Hum Genet* **97**: 114–116.
- Scherer SJ, Maier SM, Seifert M, Hanselmann RG, Zang KD, Muller-Hermelink HK, Angel P, Welter C, Scharlt M. 2000. p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. *J Biol Chem* **275**: 37469–37473.
- Schröer A, Köster F, Fischer D, Dubitscher RM, Woll-Hermann A, Diedrich K, Friedrich M, Salehin D. 2009. Immunohistochemistry of DNA mismatch repair enzyme MSH2 is not correlated with prognostic data from endometrial carcinomas. *Anticancer Res* **29**: 4833–4837.
- Schumacher B, Hofmann K, Boulton S, Gartner A. 2001. The *C. elegans* homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. *Curr Biol* **11**: 1722–1727.
- Schumacher B, Hanazawa M, Lee M-H, Nayak S, Volkmann K, Hofmann ER, Hofmann R, Hengartner M, Schedl T, Gartner A. 2005a. Translational repression of *C. elegans* p53 by GLD-1 regulates DNA damage-induced apoptosis. *Cell* **120**: 357–368.
- Schumacher B, Schertel C, Wittenburg N, Tuck S, Mitani S, Gartner A, Conradt B, Shaham S. 2005b. *C. elegans* ced-13 can promote apoptosis and is induced in response to DNA damage. *Cell Death Differ* **12**: 153–161.
- Sengupta S, Harris CC. 2005. p53: Traffic cop at the crossroads of DNA repair and recombination. *Nat Rev Mol Cell Biol* **6**: 44–55.
- Sengupta S, Linke SP, Pedoux R, Yang Q, Farnsworth J, Garfield SH, Valerie K, Shay JW, Ellis NA, Wasyluk B, et al. 2003. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. *EMBO J* **22**: 1210–1222.
- Sengupta S, Shimamoto A, Koshiji M, Pedoux R, Rusin M, Spillare EA, Shen JC, Huang LE, Lindor NM, Furuichi Y, et al. 2005. Tumor suppressor p53 represses transcription of RECQ4 helicase. *Oncogene* **24**: 1738–1748.
- Seo YR, Fishel ML, Amundson S, Kelley MR, Smith ML. 2002a. Implication of p53 in base excision DNA repair: In vivo evidence. *Oncogene* **21**: 731–737.
- Seo YR, Kelley MR, Smith ML. 2002b. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. *Proc Natl Acad Sci* **99**: 14548–14553.
- Serrano MA, Li Z, Dangeti M, Musich PR, Patrick S, Roginskaya M, Cartwright B, Zou Y. 2013. DNA-PK, ATM and ATR collaboratively regulate p53–RPA interaction to facilitate homologous recombination DNA repair. *Oncogene* **32**: 2452–2462.
- Shen Y, Zhang S, Huang X, Chen K, Shen J, Wang Z. 2014. Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells. *Biomed Res Int* **2014**: 920275.
- Shiloh Y, Ziv Y. 2013. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. *Nat Rev Mol Cell Biol* **14**: 197–210.
- Sirbu BM, Lachmayer SJ, Wülfing V, Marten LM, Clarkson KE, Lee IW, Gheorghiu L, Zou L, Powell SN, Dahm-Daphi J, et al. 2011. ATR-p53 restricts homologous recombination in response to replicative stress but does not limit DNA interstrand crosslink repair in lung cancer cells. *PLoS ONE* **6**: e23053.
- Smith ML, Chen IT, Zhan Q, O'Connor PM, Fornace AJ. 1995. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. *Oncogene* **10**: 1053–1059.
- Spillare EA, Robles AI, Wang XW, Shen JC, Yu CE, Schellenberg GD, Harris CC. 1999. p53-mediated apoptosis is attenuated in Werner syndrome cells. *Genes Dev* **13**: 1355–1360.
- Subramanian D, Griffith JD. 2002. Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases. *Nucleic Acids Res* **30**: 2427–2434.
- Subramanian D, Griffith JD. 2005. Modulation of p53 binding to Holliday junctions and 3-cytosine bulges by phosphorylation events. *Biochemistry* **44**: 2536–2544.
- Sugasawa K. 2010. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. *Mutat Res* **685**: 29–37.
- Vanasse GJ, Halbrook J, Thomas S, Burgess A, Hoekstra MF, Disteché CM, Willerford DM. 1999. Genetic pathway to

- recurrent chromosome translocations in murine lymphoma involves V(D)J recombinase. *J Clin Invest* **103**: 1669–1675.
- van Oers JMM, Edwards Y, Chahwan R, Zhang W, Smith C, Pechuan X, Schaetzlein S, Jin B, Wang Y, Bergman A, et al. 2014. The MutS β complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair. *Oncogene* **33**: 3939–3946.
- Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Freidberg EC, Evans MK, Taffe BG. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. *Nat Genet* **10**: 188–195.
- Wang XW, Tseng A, Ellis NA, Spillare EA, Linke SP, Robles AI, Seker H, Yang Q, Hu P, Beresten S, et al. 2001. Functional interaction of p53 and BLM DNA helicase in apoptosis. *J Biol Chem* **276**: 32948–32955.
- Wani MA, Zhu Q, El-Mahdy M, Venkatachalam S, Wani AA. 2000. Enhanced sensitivity to *anti*-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells. *Cancer Res* **60**: 2273–2280.
- Wani MA, El-Mahdy MA, Hamada FM, Wani G, Zhu Q, Wang Q-E, Wani AA. 2002. Efficient repair of bulky anti-BPDE DNA adducts from non-transcribed DNA strand requires functional p53 but not p21(waf1/cip1) and pRb. *Mutat Res* **505**: 13–25.
- Willers H, McCarthy EE, Wu B, Wunsch H, Tang W, Taghian DG, Xia F, Powell S. 2000. Dissociation of p53-mediated suppression of homologous recombination from G₁/S cell cycle checkpoint control. *Oncogene* **19**: 632–639.
- Wirtenberger M, Frank B, Hemminki K, Klaes R, Schmutzler RK, Wappenschmidt B, Meindl A, Kiechle M, Arnold N, Weber BHF, et al. 2006. Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. *Carcinogenesis* **27**: 1655–1660.
- Yang Q, Zhang R, Wang XW, Spillare EA, Linke SP, Subramanian D, Griffith JD, Li JL, Hickson ID, Shen JC, et al. 2002. The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. *J Biol Chem* **277**: 31980–31987.
- Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. *Cell* **70**: 937–948.
- Zaky A, Busso C, Izumi T, Chattopadhyay R, Bassiouny A, Mitra S, Bhakat KK. 2008. Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. *Nucleic Acids Res* **36**: 1555–1566.
- Zhang X, Zhu Y, Geng L, Wang H, Legerski RJ. 2009. Artemin is a negative regulator of p53 in response to oxidative stress. *Oncogene* **28**: 2196–2204.
- Zhou J, Prives C. 2003. Replication of damaged DNA in vitro is blocked by p53. *Nucleic Acids Res* **31**: 3881–3892.
- Zhou J, Ahn J, Wilson SH, Prives C. 2001. A role for p53 in base excision repair. *EMBO J* **20**: 914–923.
- Zhu Q, Wani MA, El-Mahdy M, Wani AA. 2000. Decreased DNA repair efficiency by loss or disruption of p53 function preferentially affects removal of cyclobutane pyrimidine dimers from non-transcribed strand and slow repair sites in transcribed strand. *J Biol Chem* **275**: 11492–11497.
- Zink D, Mayr C, Janz C, Wiesmüller L. 2002. Association of p53 and MSH2 with recombinative repair complexes during S phase. *Oncogene* **21**: 4788–4800.
- Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. 2004. The role of p53 in base excision repair following genotoxic stress. *Carcinogenesis* **25**: 11–19.

Cold Spring Harbor Perspectives in Medicine

p53 in the DNA-Damage-Repair Process

Ashley B. Williams and Björn Schumacher

Cold Spring Harb Perspect Med 2016; doi: 10.1101/cshperspect.a026070 originally published online April 5, 2016

Subject Collection [The p53 Protein](#)

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Shaomeng Wang, Yujun Zhao, Angelo Aguilar, et al.

Structural Evolution and Dynamics of the p53 Proteins

Giovanni Chillemi, Sebastian Kehrlöesser, Francesca Bernassola, et al.

Exploiting the p53 Pathway for Therapy

Chit Fang Cheok and David Philip Lane

The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence

Crystal A. Tonnessen-Murray, Guillermina Lozano and James G. Jackson

The Transactivation Domains of the p53 Protein

Nitin Raj and Laura D. Attardi

The Evolution of the Ribosomal Protein–MDM2–p53 Pathway

Chad Deisenroth, Derek A. Franklin and Yanping Zhang

Somatic TP53 Mutations in the Era of Genome Sequencing

Pierre Hainaut and Gerd P. Pfeifer

The Paradox of p53: What, How, and Why?

Yael Aylon and Moshe Oren

Control of Cellular Aging, Tissue Function, and Cancer by p53 Downstream of Telomeres

Caitlin M. Roake and Steven E. Artandi

Inherited TP53 Mutations and the Li–Fraumeni Syndrome

Tanya Guha and David Malkin

TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia

Evan Q. Comeaux and Charles G. Mullighan

Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53

Neil T. Pfister and Carol Prives

The Inherited p53 Mutation in the Brazilian Population

Maria Isabel Achatz and Gerard P. Zambetti

TP53 Mutations in Breast and Ovarian Cancer

Laxmi Silwal-Pandit, Anita Langerød and Anne-Lise Børresen-Dale

p53 and the Carcinogenicity of Chronic Inflammation

Andrei V. Gudkov and Elena A. Komarova

Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation

Yoav Shetzer, Alina Molchadsky and Varda Rotter

For additional articles in this collection, see <http://perspectivesinmedicine.cshlp.org/cgi/collection/>